Press Release

View printer-friendly version << Back
Juniper Pharmaceuticals to Present at Jefferies 2016 Healthcare Conference

BOSTON, May 24, 2016 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), announced today that Frank Condella, Chief Executive Officer, will present at the Jefferies 2016 Healthcare Conference in New York, NY on Wednesday, June 8, 2016 at 2:30 p.m. EDT.  

Juniper Pharmaceuticals, Inc. (PRNewsFoto/Juniper Pharmaceuticals, Inc.)

Juniper's presentation will be webcast live via www.juniperpharma.com under the 'Investors' tab, or click here.  The webcast will be archived for 90 days at the aforementioned URLs.

The women's health therapeutics company will hold a discussion period following the presentation, as well as investor meetings throughout the day.

About Juniper Pharmaceuticals
Juniper Pharmaceuticals, Inc. is focused on developing therapeutics that address unmet medical needs in women's health.  The Company is advancing a pipeline of proprietary product candidates that leverage novel intra-vaginal drug delivery technologies.  Juniper's commercial product, CRINONE® 8% (progesterone gel), is marketed by Merck KGaA, Darmstadt, Germany, in over 90 countries worldwide and by Allergan, Inc. in the U.S. Please visit www.juniperpharma.com for more information.

Juniper Pharmaceuticals™ is a trademark of Juniper Pharmaceuticals, Inc., in the U.S. and EU.

CRINONE® is a registered trademark of Merck KGaA, Darmstadt, Germany, outside the U.S. and of Allergan, Inc. in the U.S.

Contact
Amy Raskopf
Director, Corporate Communications, Juniper Pharmaceuticals, Inc.
(917) 673-5775 / ir@juniperpharma.com

To receive Juniper's press releases, SEC filings or calendar alerts by email click here
Follow us on LinkedIn  

Logo - http://photos.prnewswire.com/prnh/20150527/218998LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/juniper-pharmaceuticals-to-present-at-jefferies-2016-healthcare-conference-300273913.html

SOURCE Juniper Pharmaceuticals, Inc.